Biosimilar Development Editorial Board

Source: Biosimilar Development

Molly Burich, Director, Public Policy: Biosimilars and Reimbursement, Boehringer Ingelheim

Hubert C. Chen, MD
Medical and Scientific Advisor,
Pfenex

Hillel Cohen,
Executive Director,
Scientific Affairs,
Sandoz

Ross Day, Consulting Hospital Pharmacist, Former Director of Pharmacy, Vizient

Edric Engert, Managing Director, Abraxeolus Consulting

Francois-Xavier Frapaise, M.D., ClinExcel

Kavya Gopal,
Head of Specialty, Sandoz UK
Chair, British Biosimilars Assoc.

Matthew Harman, PharmD, MPH, Director of Pharmacy, Employers Health

Ruediger Jankowsky,
Former Managing Director,
Cinfa Biotech (Mundipharma)

HoUng Kim,
Head of Strategy and
Operations,
Celltrion

Brian Lehman, MBA, MHA, RPh., Director, Medical Account Management and Strategic Alliances, Sandoz

Rick Lozano, VP, Biosimilars & Integrated Business Development, AmerisourceBergen

Julie Maréchal-Jamil, Director Biosimilars Policy & Science,
Medicines for Europe

Sue Naeyaert, Global Government Affairs, Policy, and Pharmacoeconomics, Biosimilars, Fresenius Kabi

Ned Pojskic, Leader, Pharmacy & Health Provider Relations
Green Shield Canada

Don Stewart, CEO,
PlantForm

Alexandra Valenti, Senior Associate, Goodwin Procter LLP

Lauren Vela, Senior Director, Pacific Business Group on Health